TY - JOUR A1 - Aerts, An A1 - Eberlein, Uta A1 - Holm, Sören A1 - Hustinx, Roland A1 - Konijnenberg, Mark A1 - Strigari, Lidia A1 - van Leeuwen, Fijs W. B. A1 - Glatting, Gerhard A1 - Lassmann, Michael T1 - EANM position paper on the role of radiobiology in nuclear medicine JF - European Journal of Nuclear Medicine and Molecular Imaging N2 - With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced biological responses are expected in nuclear medicine, which need to be explored. This calls for a dedicated nuclear medicine radiobiology. Radiobiology findings and absorbed dose measurements will enable an improved estimation and prediction of efficacy and adverse effects. Moreover, a better understanding on the fundamental biological mechanisms underlying tumor and normal tissue responses will help to identify predictive and prognostic biomarkers as well as biomarkers for treatment follow-up. In addition, radiobiology can form the basis for the development of radiosensitizing strategies and radioprotectant agents. Thus, EANM believes that, beyond in vitro and preclinical evaluations, radiobiology will bring important added value to clinical studies and to clinical teams. Therefore, EANM strongly supports active collaboration between radiochemists, radiopharmacists, radiobiologists, medical physicists, and physicians to foster research toward precision nuclear medicine. KW - radionuclide therapy KW - radiobiology KW - dosimetry KW - biodosimetry KW - biomarkers Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-265595 VL - 48 IS - 11 ER - TY - THES A1 - Andermann, Paul T1 - Evaluierung der Intra- und Interobserver-Variabilität bei der 2D-Ultraschall-Schilddrüsenvolumetrie an einem Schilddrüsenphantom - Vergleich zu 3D-Ultraschall-Referenzmessungen an gesunden Probanden N2 - Mehrere Autoren haben schon die Intra- und Interobserver-Variabilität bei der Bestimmung des Schilddrüsenvolumens und knotiger Herdbefunde mit Hilfe des zweidimensionalen (2D) Ultraschalls evaluiert. Darüber hinaus wurde über Interobserver-Korrelationen für Schilddrüsenvolumenmessungen berichtet. Es gibt jedoch keine prospektive verblindete Studie, die die Intra- bzw. Interobserver-Variabilität bei der Volumenbestimmung der gesamten Schilddrüse an gesunden Probanden bzw. einzelner Knoten unterschiedlicher Echogenität an einem Phantom untersucht hat. Die Ergebnisse der Einzelstudien sollen hier vorgestellt und – soweit möglich – miteinander verglichen werden. Im Rahmen einer quantitativen Studie mit dem hier präsentierten Schilddrüsenphantom soll die Intra- und Interobserver-Variabilität bei der 2D-Ultraschallvolumetrie einzelner Knoten unterschiedlicher Größe und Echogenität und der Schilddrüsenlappen evaluiert werden. Da Schilddrüsenknoten wegen des geringeren Volumens und ihrer oft unscharfen Randkontur schwieriger zu entdecken und auszumessen sind als die Gesamtschilddrüse, soll untersucht werden, welche Größenordnungen des Messfehlers auftreten und in welcher Relation sie zueinander stehen. Außerdem soll der methodenimmanente Fehler quantifiziert und detektierbare Volumenänderungen erfassbar gemacht werden. Bisher war in der Schilddrüsensonographie kein geeignetes Phantom verfügbar, das kommerziell erhältlich ist und mit dem qualitativ unterschiedliche intrathyreoidale Herdbefunde untersucht werden können. Die vorliegende Studie an gesunden Probanden hatte das primäre Ziel, die Frage nach der Quantifizierbarkeit von Unsicherheitsfaktoren in der Schilddrüsenvolumetrie durch den konventionellen 2D-Ultraschall im Vergleich zu 3D-Referenzvolumina bei gesunden Erwachsenen möglichst exakt zu beantworten und die Untersucherabhängigkeit der Methode zu demonstrieren. Damit soll die Genauigkeit (Richtigkeit und Präzision) der sonographischen Schilddrüsendiagnostik mathematisch erfasst und eine bessere Bewertungsgrundlage für die Frage nach der Reproduzierbarkeit von Ultraschall-Volumenbestimmungen der Schilddrüse und ihrer pathologischen Veränderungen geschaffen werden. Hierfür wurden möglichst aussagekräftige statistische Parameter wie die Intra- und Interobserver-Variabilität, der systematische und zufällige Fehler, der reine Fehler der Messmethode, minimale, sicher detektierbare Volumenänderungen und im Rahmen einer multivariaten Reliabilitätsanalyse die Reliabilitätskoeffizienten untersucht. Ein weiteres Ziel dieser Studie bestand darin, die Reliabilität der in der klinischen Routine benutzten Ellipsoidformel zur Berechnung des Schilddrüsenvolumens zu überprüfen. KW - Intraobserver-Variabilität KW - Interobserver-Variabilität KW - Ultraschall KW - Schilddrüsenvolumetrie KW - Schilddrüsenphantom Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-23434 ER - TY - JOUR A1 - Angheloiu, George O. A1 - Hänscheid, Heribert A1 - Wen, Xiaoyan A1 - Capponi, Vincent A1 - Anderson, William D. A1 - Kellum, John A. T1 - Experimental first-pass method for testing and comparing sorbent polymers used in the clearance of iodine contrast materials JF - Blood Purification N2 - Background: Sorbents have been shown to adsorb iodinated radiocontrast media. Objective: In this study we describe a simple method to compare various sorbents in terms of capacity to adsorb radiocontrast media. Methods: Iodixanol solution was injected into columns filled with three types of sorbent at filtration velocities of increasing magnitude. Two variables of interest – contrast removal rate and matched iodine retention (MIR) – were calculated to measure the adsorption efficiency and the mass of contrast iodine adsorbed versus sorbent used, respectively. Results: The highest contrast removal and MIR for Porapak Q, CST 401 and Amberlite XAD4 were 41, 38 and 16% (p = 0.22 and 0.0005 for comparisons between Porapak Q-CST 401 and CST 401-Amberlite XAD4) and 0.060, 0.055 and 0.024, respectively (p = 0.18 and 0.0008). Extrapolation to a clinical scenario may suggest that removal of 8 ml iodixanol could be achieved by masses of sorbents of 43, 47 and 107 g, respectively. Conclusion: In this study we set a benchmark for comparing the radiocontrast-adsorbing efficiency of polymer sorbents during first-pass experiments, using a readily available methodology. KW - adsorption KW - acute renal failure KW - sorbents KW - iodine contrast Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-199118 SN - 0253-5068 SN - 1421-9735 N1 - Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. VL - 34 IS - 1 ER - TY - JOUR A1 - Aster, Hans-Christoph A1 - Romanos, Marcel A1 - Walitza, Susanne A1 - Gerlach, Manfred A1 - Mühlberger, Andreas A1 - Rizzo, Albert A1 - Andreatta, Marta A1 - Hasenauer, Natalie A1 - Hartrampf, Philipp E. A1 - Nerlich, Kai A1 - Reiners, Christoph A1 - Lorenz, Reinhard A1 - Buck, Andreas K. A1 - Deserno, Lorenz T1 - Responsivity of the striatal dopamine system to methylphenidate — A within-subject I-123-β-CIT-SPECT study in male children and adolescents with attention-deficit/hyperactivity disorder JF - Frontiers in Psychiatry N2 - Background: Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning. Methods Thirteen adolescent male patients (9–16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH. Results On-MPH status was associated with a highly significant change (−29.9%) of striatal DAT BP as compared to off-MPH (t = −4.12, p = 0.002). A more pronounced change in striatal DAT BP was associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r = 0.68, p = 0.01). Striatal DAT BP off-MPH, but not on-MPH, was associated with higher symptom ratings (Pearson r = 0.56, p = 0.04). Conclusion Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity. KW - methylphenidate KW - attention deficit/hyperactivity disorder (ADHD) KW - striatum KW - single photon emission computed tomography (SPECT) KW - responsivity KW - caudate nucleus KW - dopamine transporter (DAT) Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-270862 SN - 1664-0640 VL - 13 ER - TY - JOUR A1 - Baur, Johannes A1 - Schedelbeck, Ulla A1 - Pulzer, Alina A1 - Bluemel, Christina A1 - Wild, Vanessa A1 - Fassnacht, Martin A1 - Steger, U. T1 - A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma JF - BMC Surgery N2 - Background Solitary metastases to the pancreas are rare. Therefore the value of resection in curative intention remains unclear. In the literature there are several promising reports about resection of solitary metastasis to the pancreas mainly of renal origin. Case presentation Here we report for the first time on the surgical therapy of a 1.5 cm solitary pancreatic metastasis of an adrenocortical carcinoma. The metastasis occurred almost 6 years after resection of the primary tumor. A partial pancreatoduodenectomy was performed and postoperatively adjuvant mitotane treatment was initiated. During the follow-up of 3 years after surgery no evidence of tumor recurrence occurred. Conclusion Resection of pancreatic tumors should be considered, even if the mass is suspicious for metastatic disease including recurrence of adrenocortical cancer. KW - surgical treatment KW - adrenocortical KW - carcinoma metastases to pancreas Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126130 VL - 15 IS - 93 ER - TY - THES A1 - Becker, Kilian T1 - Entwicklung eines 3D-Ganzkörper-Ultraschalls an Kleintieren für morphologische Bildgebung, Volumetrie und Bildfusion mit PET T1 - Development of a 3D whole-body ultrasound in small animals for morphological imaging, volumetry and image fusion with PET N2 - Einleitung: Ultraschall wird seit mehr als 50 Jahren in der Medizin eingesetzt und ist mittlerweile ein unverzichtbares diagnostisches Verfahren, es erlaubt eine nicht-invasive Darstellung der Morphologie und Funktion von Organen in Echtzeit. In der Kleintierbildgebung dominieren bisher zur morphologischen Bildgebung Computertomographie (CT) und Magnetresonanztomographie (MRT). Daher wurde in der vorliegenden Arbeit die Idee entwickelt, die morphologischen Informationen des 3D-Ultraschalls (3D-US) für Untersuchungen an Kleintieren zu verwenden, außerdem sollten Methoden zur multimodalen Bildgebung und Bildfusion von 3D-US und Kleintier-Positronenemissionstomographie (PET) entwickelt werden. Der Vorteil des Ultraschalls gegenüber dem Kleintier-CT liegt in der fehlenden Strahlenbelastung und der guten Verfügbarkeit, was besonders für Verlaufsstudien von Interesse ist. Methoden und Ergebnisse: Zur Bildoptimierung wurde ein Fadenphantom entwickelt, welches aufgrund der feinen Strukturen die qualitative als auch quantitative Bestimmung der Auflösung ermöglicht. Die Vorarbeiten am Fadenphantom konnten exzellent die Probleme des 3D-Ultraschalls mit der achsenabhängigen Auflösung zeigen und ermöglichten eine schnelle Beurteilung der Bildqualität. Hier bestehen Einsatzmöglichkeiten in der Bewertung verschiedener Ultraschallgeräte bezüglich der Tauglichkeit für 3D-Datenaquisition. Zur reproduzierbaren Lagerung von Mäusen wurde eine Schallkopfführung ein sowohl für 3D-US als auch Kleintier-PET kompatibler Tierhalter entwickelt. Die Maus lag zur Untersuchung im angewärmten Wasserbad auf dem Tierhalter fixiert, mit Inhalationsanästhesie und Sauerstoff über eine Atemmaske versorgt. Der Zeitaufwand für eine 3D-US-Untersuchung betrug für die Akquisition etwa eine Minute. Die generierten Ultraschalldatensätze waren von guter Qualität, Strukturen wie Leber, Nieren, Blase, Wirbelsäule und Lunge konnten selbst bei kleinen Mäusen von unter 20 Gramm Körpergewicht gut dargestellt werden. Zur Validierung des 3D-Ultraschalls wurde das Volumen verschiedener Organe und Tumore bestimmt und mit dem Goldstandard verglichen. Um die Koregistrierung mit der Kleintier-PET zu ermöglichen, wurden auf dem Tierhalter drei „fiducial markers“ angebracht, die Position und Orientierung eindeutig definieren. Die Kleintier-PET-Untersuchungen wurden nach standardisierten Protokollen durchgeführt. Die anschließende Bildfusion erfolgte mittels der frei verfügbaren Software "Amide". Diskussion: Mit dem in dieser Arbeit beschriebenen Verfahren ist eine standardisierte Gewinnung von 3D-US-Datensätzen an Kleintieren möglich; zusätzlich konnte die Machbarkeit der Bildfusion mit PET-Datensätzen gezeigt werden. Der Einsatz des 3D-Ultraschalls in longitudinalen Studien, zum Beispiel zur Beurteilung der Tumorprogression, ist vorstellbar. Die Zuverlässigkeit der volumetrischen Berechnungen ist für größere Organvolumina gut, bei kleineren Volumina besteht noch Optimierungsbedarf. Weitere Verbesserungen könnten durch den Einsatz von speziellen Schallköpfen und höheren Schallfrequenzen erzielt werden. N2 - Introduction: Ultrasound has been used for more than 50 years in medicine and has become a indispensable diagnostic tool, it allows a non-invasive imaging of the morphology and function of organs in real time. Small animal morphological imaging is now dominated by CT and MRI. For present study the idea to use morphological information of the 3D-ultrasound for examination of small animals was developed, these data should be used for image fusion of 3D ultrasound and small-animal PET. The advantage of ultrasound compared to the small-animal CT is the lack of radiation exposure and the good availability, which is especially for longitudinal studies of interest. Methods and Results: For image enhancement, a thread phantom was developed, fine structures facilitate qualitative and quantitative analysis of spatial resolution. Preliminary work on the thread phantom was excellent for investigate problems of 3D ultrasound with the axis-dependent resolution. There are potential applications for evaluating different ultrasonic devices in their suitability for 3D data acquisition. For the reproducible bedding of mice a guide bar for ultrasound transducer and a compatible holder for 3D-US and PET was developed. The mouse was bedded in the heated water bath fixed to the holder, applied inhalation anesthesia and oxygen through a breathing mask. The time required for a 3D ultrasound examination was for the acquisition of about one minute. The generated ultrasound data sets were of good quality, structures such as liver, kidney, bladder, spine and lungs were even in the case of small mice of 20 gram well represented. For validation of the 3D ultrasound volumes of various organs and tumors were determined and compared with gold standard. To allow coregistration with the microPET, three "fiducial markers" were attached to define the position and orientation. PET studies were performed according to standardized protocols. The subsequent image fusion was performed using the software "amide”. Discussion: In this study a standardized procedure for 3D-US of small animals was developed, in addition, the feasibility of image fusion with PET data sets was shown. The use of 3D ultrasound in longitudinal studies, for example, to assess tumor progression, is conceivable. The reliability of the volumetric calculations is good for large organ volumes, with smaller volumes, there is still need for improvement. Further improvements could be achieved through the use of special transducers and higher ultrasound frequencies. KW - Ultraschalldiagnostik KW - Nuklearmedizin KW - Würzburg / Klinik und Poliklinik für Nuklearmedizin KW - Molekulare Bildgebung KW - 3D-Ultraschall KW - dreidimensionaler Ultraschall KW - PET KW - Positronenemissionstomographie KW - Bildfusion KW - 3D ultrasound KW - three-dimensional ultrasound KW - PET KW - positron emission tomography KW - image fusion Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-55916 ER - TY - JOUR A1 - Beykan, Seval A1 - Dam, Jan S. A1 - Eberlein, Uta A1 - Kaufmann, Jens A1 - Kjærgaard, Benedict A1 - Jødal, Lars A1 - Bouterfa, Hakim A1 - Bejot, Romain A1 - Lassmann, Michael A1 - Jensen, Svend Borup T1 - \(^{177}\)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model JF - EJNMMI Research N2 - Background \(^{177}\)Lu is used in peptide receptor radionuclide therapies for the treatment of neuroendocrine tumors. Based on the recent literature, SST2 antagonists are superior to agonists in tumor uptake. The compound OPS201 is the novel somatostatin antagonist showing the highest SST2 affinity. The aim of this study was to measure the in vivo biodistribution and dosimetry of \(^{177}\)Lu-OPS201 in five anesthetized Danish Landrace pigs as an appropriate substitute for humans to quantitatively assess the absorbed doses for future clinical applications. Results \(^{177}\)Lu-OPS201 was obtained with a specific activity ranging from 10 to 17 MBq/μg. Prior to administration, the radiochemical purity was measured as s > 99.7 % in all cases. After injection, fast clearance of the compound from the blood stream was observed. Less than 5 % of the injected activity was presented in blood 10 min after injection. A series of SPECT/CT and whole-body scans conducted until 10 days after intravenous injection showed uptake mostly in the liver, spine, and kidneys. There was no visible uptake in the spleen. Blood samples were taken to determine the time-activity curve in the blood. Time-activity curves and time-integrated activity coefficients were calculated for the organs showing visible uptake. Based on these data, the absorbed organ dose coefficients for a 70-kg patient were calculated with OLINDA/EXM. For humans after an injection of 5 GBq \(^{177}\)Lu-OPS201, the highest predicted absorbed doses are obtained for the kidneys (13.7 Gy), the osteogenic cells (3.9 Gy), the urinary bladder wall (1.8 Gy), and the liver (1.0 Gy). No metabolites of 177Lu-OPS201 were found by radio HPLC analysis. None of the absorbed doses calculated will exceed organ toxicity levels. Conclusions The \(^{177}\)Lu-OPS201 was well tolerated and caused no abnormal physiological or behavioral signs. In vivo distributions and absorbed doses of pigs are comparable to those observed in other publications. According to the biodistribution data in pigs, presented in this work, the expected radiation exposure in humans will be within the acceptable range. KW - lutetium-177 KW - JR11 KW - antagonist KW - dosimetry KW - neuroendocrine tumor (NET) KW - OPS201 KW - pig model KW - PRRT Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-146888 VL - 6 IS - 50 ER - TY - JOUR A1 - Beykan, Seval A1 - Fani, Melpomeni A1 - Jensen, Svend Borup A1 - Nicolas, Guillaume A1 - Wild, Damian A1 - Kaufmann, Jens A1 - Lassmann, Michael T1 - In vivo biokinetics of \(^{177}\)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry JF - Contrast Media & Molecular Imaging N2 - Introduction. \(^{177}\)Lu-OPS201 is a high-affinity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroendocrine tumors. The aim is to find the optimal scaling for dosimetry and to compare the biokinetics of \(^{177}\)Lu-OPS201 in animals and humans. Methods. Data on biokinetics of \(^{177}\)Lu-OPS201 were analyzed in athymic nude Foxn1\(^{nu}\) mice (28 F, weight: 26 ± 1 g), Danish Landrace pigs (3 F-1 M, weight: 28 ± 2 kg), and patients (3 F-1 M, weight: 61 ± 17 kg) with administered activities of 0.19–0.27 MBq (mice), 97–113 MBq (pigs), and 850–1086 MBq (patients). After euthanizing mice (up to 168 h), the organ-specific activity contents (including blood) were measured. Multiple planar and SPECT/CT scans were performed until 250 h (pigs) and 72 h (patients) to quantify the uptake in the kidneys and liver. Blood samples were taken up to 23 h (patients) and 300 h (pigs). In pigs and patients, kidney protection was applied. Time-dependent uptake data sets were created for each species and organ/tissue. Biexponential fits were applied to compare the biokinetics in the kidneys, liver, and blood of each species. The time-integrated activity coefficients (TIACs) were calculated by using NUKFIT. To determine the optimal scaling, several methods (relative mass scaling, time scaling, combined mass and time scaling, and allometric scaling) were compared. Results. A fast blood clearance of the compound was observed in the first phase (<56 h) for all species. In comparison with patients, pigs showed higher liver retention. Based on the direct comparison of the TIACs, an underestimation in mice (liver and kidneys) and an overestimation in pigs’ kidneys compared to the patient data (kidney TIAC: mice = 1.4 h, pigs = 7.7 h, and patients = 5.8 h; liver TIAC: mice = 0.7 h, pigs = 4.1 h, and patients = 5.3 h) were observed. Most similar TIACs were obtained by applying time scaling (mice) and combined scaling (pigs) (kidney TIAC: mice = 3.9 h, pigs = 4.8 h, and patients = 5.8 h; liver TIAC: mice = 0.9 h, pigs = 4.7 h, and patients = 5.3 h). Conclusion. If the organ mass ratios between the species are high, the combined mass and time scaling method is optimal to minimize the interspecies differences. The analysis of the fit functions and the TIACs shows that pigs are better mimicking human biokinetics. KW - medicine KW - neuroendocrine tumors KW - biokinetics KW - \(^{177}\)Lu-OPS201 KW - dosimetry Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-177382 VL - 2019 ER - TY - THES A1 - Blasl, Christiana T1 - Chromatografischer Nachweis endogen radioiodierter Verbindungen im Urin von Patienten mit differenziertem Schilddrüsenkarzinom nach Iod-131-Ganzkörperszintigrafie T1 - Chromatographic identification of endogenously radioiodinated thyroid products in urine of patients with differentiated thyroid carcinoma after I-131-whole-body-scintigraphy N2 - Der Follow-UP von Patienten mit differenziertem Schilddrüsenkarzinom (DTC) wird konventionell mit I-131-Ganzkörperzintigrafie (GKS) und Bestimmung des Serumthyreoglobulins (hTg) durchgeführt. Wegen der Inzidenz von 15%-20% diskordanter Resultate entwickelte Bianchi et al. (J Nucl Med 1993; 34: 2032-2037) die Serumchromatografie von endogen radioiodiertem Triiodthyronin (L-T3) und Thyroxin (L-T4) bei Patienten mit DTC nach oraler Applikation von I-131. Da im Rahmen des Iodstoffwechsels auch radioiodierte Verbindungen im Urin erscheinen, versuchten wir eine Urinchromatografiemethode zu entwickeln, basierend auf der Annahme, dass ein pathologischer I-131-Uptake, wenngleich zu niedrig um im GKS erkannt zu werden, gleichwohl über endogen iodierte Schilddrüsenprodukte im Urin nachgewiesen werden kann. In der Urinchromatografie konnten die Ergebnisse der Serumchromatografie nicht erreicht werden. N2 - Patients with DTC are conventionally followed up with serial I-131- whole-body-scintigraphy (WBS) and serum thyroglobulin (hTg) measurements. Given the 15%-20% incidence of discordant results Bianchi et al. (J Nucl Med 1993; 34: 2032-2037) established the serum chromatographic identification of endogenously radioiodinated thyroid hormones after I-131-WBS in the follow-up of patients with DTC. We tried to establish an urine chromatographic method of patients with DTC, based on the assumption that I-131-uptake, though too low to be detected by I-131-WBS, could be assayed in urine as endogenously labeled and excreted thyroid products. The urine chromatographic method did not show the good results of the serum chromatographic method. KW - Differenziertes Schilddrüsenkarzinom KW - I-131-Ganzkörperzintigrafie KW - Thyreoglobulin (hTg) KW - Urinchromatografie KW - Serumchromatografie KW - differentiated thyroid carcinoma KW - I-131-whole-body-scintigraphy KW - thyroglobulin (hTg) KW - urine chromatographic method KW - serum chromatographic method Y1 - 2004 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-12726 ER - TY - JOUR A1 - Bluemel, Christina A1 - Linke, Fraenze A1 - Herrmann, Ken A1 - Simunovic, Iva A1 - Eiber, Matthias A1 - Kestler, Christian A1 - Buck, Andreas K. A1 - Schirbel, Andreas A1 - Bley, Thorsten A. A1 - Wester, Hans-Juergen A1 - Vergho, Daniel A1 - Becker, Axel T1 - Impact of \(^{68}\)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy JF - EJNMMI Research N2 - Background Salvage radiotherapy (SRT) is clinically established in prostate cancer (PC) patients with PSA persistence or biochemical relapse (BCR) after prior radical surgery. PET/CT imaging prior to SRT may be performed to localize disease recurrence. The recently introduced \(^{68}\)Ga-PSMA outperforms other PET tracers for detection of recurrence and is therefore expected also to impact radiation planning. Forty-five patients with PSA persistence (16 pts) or BCR (29 pts) after prior prostatectomy, scheduled to undergo SRT of the prostate bed, underwent \(^{68}\)Ga-PSMA PET/CT. The median PSA level was 0.67 ng/ml. The impact of \(^{68}\)Ga-PSMA PET/CT on the treatment decision was assessed. Patients with oligometastatic (≤5 lesions) PC underwent radiotherapy (RT), with the extent of the RT area and dose escalation being based on PET positivity. Results Suspicious lesions were detected in 24/45 (53.3 %) patients. In 62.5 % of patients, lesions were only detected by 68Ga-PSMA PET. Treatment was changed in 19/45 (42.2 %) patients, e.g., extending SRT to metastases (9/19), administering dose escalation in patients with morphological local recurrence (6/19), or replacing SRT by systemic therapy (2/19). 38/45 (84.4 %) followed the treatment recommendation, with data on clinical follow-up being available in 21 patients treated with SRT. All but one showed biochemical response (mean PSA decline 78 ± 19 %) within a mean follow-up of 8.12 ± 5.23 months. Conclusions \(^{68}\)Ga-PSMA PET/CT impacts treatment planning in more than 40 % of patients scheduled to undergo SRT. Future prospective studies are needed to confirm this significant therapeutic impact on patients prior to SRT. KW - prostate cancer KW - salvage radiotherapy KW - PSMA KW - PET/CT KW - recurrence Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-147798 VL - 6 IS - 78 ER -